Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Nov 24;4(22):5716-5721.
doi: 10.1182/bloodadvances.2020003345.

SF3B1-mutant CMML defines a predominantly dysplastic CMML subtype with a superior acute leukemia-free survival

Kitsada Wudhikarn  1   2 , Sanam Loghavi  3 , Abhishek A Mangaonkar  1 , Aref Al-Kali  1 , Moritz Binder  1 , Ryan Carr  1 , Kaaren Reichard  4 , Christy Finke  1 , Matthew Howard  4 , Naseema Gangat  1 , Ayalew Tefferi  1 , Rami Komrokji  5 , Najla Ali  4 , Terra Lasho  1 , Rhett Ketterling  4 , Eric Padron  4 , Mrinal M Patnaik  1
Affiliations
Comment

SF3B1-mutant CMML defines a predominantly dysplastic CMML subtype with a superior acute leukemia-free survival

Kitsada Wudhikarn et al. Blood Adv. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: M.M.P. has served on the advisory board of StemLine Pharmaceuticals. E.P. has received research funding from Kura Oncology, Incyte, and Bristol Myers Squibb and honoraria from Novartis and Taiho. The remaining authors declare no competing financial interests.

Figures

Figure 1.
Figure 1.
Phenotypic correlates, molecular features, and survival outcomes of SF3B1MTCMML, SF3B1WTCMML, and SF3B1MTMDS-RS. (A-B) Mutational distribution of myeloid-relevant mutations in SF3B1MT CMML and SF3B1WT CMML (A) and SF3B1MT CMML and SF3B1MT MDS-RS (B). Asterisks denote statistically significant differences between the 2 groups. (C) Median VAF burdens of SF3B1 mutations in SF3B1MT CMML and SF3B1MT MDS-RS. (D) Amino acid changes in SF3B1 secondary to SF3B1 mutations in CMML and MDS-RS. (E) Pertinent outcomes including OS and acute leukemia–free survival (ALFS) among SF3B1MT CMML, SF3B1WT CMML, and SF3B1MT MDS-RS patients.
See this image and copyright information in PMC

Comment on

  • SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS.
    Malcovati L, Stevenson K, Papaemmanuil E, Neuberg D, Bejar R, Boultwood J, Bowen DT, Campbell PJ, Ebert BL, Fenaux P, Haferlach T, Heuser M, Jansen JH, Komrokji RS, Maciejewski JP, Walter MJ, Fontenay M, Garcia-Manero G, Graubert TA, Karsan A, Meggendorfer M, Pellagatti A, Sallman DA, Savona MR, Sekeres MA, Steensma DP, Tauro S, Thol F, Vyas P, Van de Loosdrecht AA, Haase D, Tüchler H, Greenberg PL, Ogawa S, Hellstrom-Lindberg E, Cazzola M. Malcovati L, et al. Blood. 2020 Jul 9;136(2):157-170. doi: 10.1182/blood.2020004850. Blood. 2020. PMID: 32347921 Free PMC article. Review.

References

    1. Malcovati L, Stevenson K, Papaemmanuil E, et al. . SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS. Blood. 2020;136(2):157-170. - PMC - PubMed
    1. Arber DA, Orazi A, Hasserjian R, et al. . The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391-2405. - PubMed
    1. Patnaik MM, Lasho TL, Finke CM, et al. . Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic leukemia: prevalence, clinical correlates, and prognostic relevance. Am J Hematol. 2013;88(3):201-206. - PubMed
    1. Coltro G, Mangaonkar AA, Lasho TL, et al. . Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)-a study of 1084 patients. Leukemia. 2020;34(5):1407-1421. - PubMed
    1. Greenberg PL, Tuechler H, Schanz J, et al. . Revised International Prognostic Scoring System for myelodysplastic syndromes. Blood. 2012;120(12):2454-2465. - PMC - PubMed